



## Product Information

**Product ID** Z0222

**CAS No.** 107753-78-6

**Chemical Name**

**Synonym**

**Formula** C<sub>31</sub>H<sub>33</sub>N<sub>3</sub>O<sub>6</sub>S

**Formula Wt.** 575.68

**Melting Point** 138-140° C


**Purity** ≥98%

**Solubility** Soluble in DMSO (25 mg/ml).

**Store Temp** Ambient

**Ship Temp** Ambient

**Description** Zafirlukast is commonly recognized as a leukotriene receptor antagonist which is used in the treatment of asthma. It is found to be a potent inhibitor of VEGF-C/Nrp2. Research on topical usage suggests that zafirlukast may also be effective in preventing capsular contracture and reducing capsule formation of gel implants, a complication arising after breast implant surgery. TEST!!!!!!



## Pricing and Availability

**Bulk quantities available upon request**

Product ID	Size	List Price
Z0222	10 mg	\$34.80
Z0222	50 mg	\$138.90
Z0222	100 mg	\$231.50

**References** Oda S, Fujiwara R, Kutsuno Y, et al. Targeted screen for human UDP-glucuronosyltransferases inhibitors and the evaluation of potential drug-drug interactions with zafirlukast. *Drug Metabolism and Disposition*. 2015 Jun; 43(6):812-818. PMID: 25834030.

Bandaru S, Marri VK, Kasera P, et al. Structure based virtual screening of ligands to identify cysteinyl leukotriene receptor 1 antagonist. *Bioinformatics*. 2014 Oct 30; 30(10):652-657. PMID: 25489175.

Kang SH, Shin KC, Kim WS, et al. The preventive effect of topical zafirlukast instillation for peri-implant capsule formation in rabbits. *Archives of Plastic Surgery*. 2015 Mar; 42(2):179-185. PMID: 25798389.

**Caution:** This product is intended for laboratory and research use only. It is not for human or drug use.